Fezakinumab: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 30: | Line 30: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
<gallery> | |||
File:b&jn=2016&sj=2016.05&sc=2016.05.4|b&jn=2016&sj=2016.05&sc=2016.05.4 | |||
File:b&jn=2016&sj=2016.05&sc=2016.05.4|b&jn=2016&sj=2016.05&sc=2016.05.4 | |||
</gallery> | |||
Revision as of 23:48, 24 February 2025
Fezakinumab is an experimental drug that is being studied for the treatment of various autoimmune diseases. It is a human monoclonal antibody that targets the interleukin-22 (IL-22) protein, a cytokine involved in inflammatory responses.
Mechanism of Action
Fezakinumab works by binding to the IL-22 protein and preventing it from interacting with its receptor on the surface of cells. This blocks the signal that triggers inflammation, thereby reducing the symptoms of autoimmune diseases.
Clinical Trials
Fezakinumab has been tested in several clinical trials for conditions such as psoriasis, rheumatoid arthritis, and Crohn's disease. While results have been promising, further research is needed to determine the drug's long-term safety and efficacy.
Side Effects
As with any drug, fezakinumab may cause side effects. These can include nausea, headache, and injection site reactions. Patients should discuss potential side effects with their healthcare provider before starting treatment.
Future Research
Future research on fezakinumab will focus on determining the optimal dosing regimen, understanding how the drug works in different patient populations, and exploring its potential use in other autoimmune diseases.
